WVEHIGH SIGNALFINANCIAL10-K

WVE substantially strengthened its cash position while operating losses roughly doubled and the company refined its strategic focus around three lead hepatic/metabolic RNA medicine programs.

The dramatic improvement in cash position (nearly doubling to $602M) provides significant runway for operations, likely from equity financing or partnership proceeds. However, operating losses roughly doubled while R&D spending increased modestly, suggesting either one-time charges or declining operational efficiency that warrants investor scrutiny.

Comparing 2026-02-26 vs 2025-03-04View on EDGAR →
FINANCIAL ANALYSIS

WVE's balance sheet strengthened dramatically with cash nearly doubling to $602M and total assets growing substantially, while liabilities decreased modestly. Operating performance deteriorated significantly with losses roughly doubling despite only moderate R&D expense increases, and operating cash burn increased to $187.5M. The enhanced cash position provides substantial operational runway, but the widening losses relative to spending growth raises questions about cost management and operational efficiency.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+99.3%
$302.1M→$602.1M

Cash position surged 99.3% — strong cash generation or capital raise providing significant financial cushion.

Operating Income
P&L
-95.1%
-$110.4M→-$215.4M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Assets
Balance Sheet
+91.9%
$320.4M→$614.8M

Current assets grew 91.9% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+81.3%
$352.2M→$638.5M

Asset base grew 81.3% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
-24.1%
-$151.0M→-$187.5M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Capital Expenditure
Cash Flow
-23.5%
$938K→$718K

Capex reduced 23.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
-16.7%
$134.8M→$112.3M

Liabilities reduced 16.7% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
+14.5%
$159.7M→$182.8M

R&D investment increased 14.5% — signals commitment to future product development, though near-term margin impact.

Current Liabilities
Balance Sheet
-14.3%
$111.0M→$95.1M

Current liabilities reduced — improved short-term financial position and working capital health.

Accounts Receivable
Balance Sheet
-10.3%
$1.4M→$1.3M

Receivables declined — improved collection efficiency or conservative revenue recognition.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-04
ADDED
The number of outstanding ordinary shares of the registrant as of February 19, 2026 was 188,254,954 .
Our toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our pipeline is focused on our obesity (WVE-007), alpha-1 antitrypsin deficiency ( AATD ) (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs for Duchenne muscular dystrophy ( DMD ) and Huntington s disease ( HD ), as well as several preclinical programs utilizing our versatile RNA medicines platform.
We are actively advancing programs across modalities, including RNA interference ( RNAi ) (silencing), RNA editing, which uses novel A-to-I RNA editing oligonucleotides ( AIMers ), antisense silencing, and splicing.
We have also advanced novel bifunctional modalities designed to silence multiple targets or silence one target while simultaneously editing or upregulating another unique target.
We are currently prioritizing lead programs that use GalNAc delivery for hepatic and metabolic diseases, each of which have potential to translate powerful human genetic insights into potentially transformational RNA medicines: WVE-007 is a GalNAc-conjugated siRNA (SpiNA design) targeting inhibin E ( INHBE ) for obesity; WVE-006 is a GalNAc-conjugated RNA editing oligonucleotide (AIMer) for AATD; WVE-008 is a GalNAc-conjugated RNA editing oligonucleotide (AIMer) for PNPLA3 I148M liver disease.
Our clinical-stage portfolio also includes WVE-N531, an exon 53 splicing oligonucleotide for DMD, and WVE-003, an allele-selective oligonucleotide designed to lower mutant huntingtin ( mHTT ) protein and preserve healthy, wild-type huntingtin ( wtHTT ) protein.
We are also advancing several emerging siRNA and RNA editing programs targeting both hepatic and extra-hepatic tissues.
In the United States, an estimated 42% of the adult population is living with obesity, and there are an estimated 175 million people in the United States and Europe and over one billion people globally, living with obesity.
Although GLP-1s induce weight loss, there remains a substantial unmet need in obesity, as GLP-1s lead to weight loss at the expense of muscle mass.
REMOVED
The number of outstanding ordinary shares of the registrant as of February 24, 2025 was 153,486,021 .
Our toolkit of RNA-targeting modalities includes RNA editing, splicing, silencing using RNA interference ( siRNA") and antisense silencing, providing us with unique capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our diversified pipeline includes clinical programs in obesity, alpha-1 antitrypsin deficiency ( AATD ), Duchenne muscular dystrophy ( DMD ), and Huntington s disease ( HD ), as well as several preclinical programs utilizing our versatile RNA medicines platform.
We are actively advancing programs using four distinct modalities, including novel A-to-I RNA editing oligonucleotides ( AIMers ).
These modalities include: RNA editing, which uses AIMers that are designed to target single bases on an RNA transcript and recruit endogenous ADAR enzymes that naturally possess the ability to change an adenine (A) to an inosine (I), which cells read as guanine (G).
This approach enables both the correction of G-to-A point mutations and the modulation of RNA to either upregulate protein expression, modify protein-protein interactions, or alter RNA folding and processing.
AIMers are short in length, fully chemically modified, and use our novel chemistry, which make them distinct from other ADAR-mediated editing approaches.
6 Antisense (silencing) , which uses our oligonucleotide designed to bind to a specific sequence in a target RNA strand that encodes a disease-associated protein or pathogenic RNA.
The resulting double-stranded molecule ( duplex ) is then recognized by a cellular enzyme called RNase H, which cleaves, or cuts, the target RNA in the duplex, thereby preventing the disease-associated protein from being made.
RNA interference (RNAi ) (silencing) , which uses our double-stranded RNAs called siRNAs to engage the RNAi machinery known as the RNA-induced silencing complex ( RISC ) and to silence a target RNA that is either pathogenic itself or encodes a disease-associated protein, thereby preventing the accumulation of the pathogenic species (RNA or protein).
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →